Shares in KalVista Pharmaceuticals shed more than half their value in Tuesday morning trading, after the company revealed it halted a mid-stage clinical trial of an experimental rare disease drug due to safety concerns.
The study had enrolled 33 people with a genetic condition called hereditary angioedema, which causes painful and unpredictable swelling attacks. Seven experienced elevations in liver enzymes that, while asymptomatic, were judged to be serious enough to stop testing.